Effect of Aranidipine on Ambulatory Blood Pressure and Ambulatory Arterial Stiffness Index in Patients with Mild to Moderate Essential Hypertension

Objective By means of ambulatory blood pressure monitoring(ABPM) to evaluate the effect of Aranidipine enteric-coated capsules on blood pressure and ambulatory arterial stiffness index(AASI) in patients with mild to moderate essential hypertension.Methods Open clinical trials were adopted.After 2 weeks of placebo run-in period,Seventy-four patients with 95 mm Hg≤diastolic blood pressure(DBP) 110 mm Hg(1 mm Hg = 0.133 kPa) and/or 140 mm Hg≤systolic blood pressure(SBP) 180 mm Hg were treated by Aranidipine(5 mg/day) for 4 weeks.If the clinical sitting SBP 140 mm Hg and DBP 90 mm Hg at 4th week,Aranidipine dosage(5 mg/day) remained;if not,Aranidipine(10 mg/day) was given for another 4 weeks.If the SBP 140 mm Hg and DBP 90 mm Hg at 8th week,Aranidipine(5mg/day or 10 mg/day respectively) was given constantly;if not,Aranidipine(20 mg/day) was given for another 4 weeks.The 24 h ABPM was taken before and after the treatment respectively.Results Among the 74 cases,there were 7 shedding or deleted,and then 67 who were enrolled in the intention-to-treat analysis(ITT).(1) After 12 weeks treatment with Aranidipine,the readings of mean 24 h SBP/DBP were significantly reduced by(14 ± 13) /11(-5,38) mm Hg,as compared with the baseline(P 0.05).Trough/peak(T/P) ratios of SBP and DBP in responders were 75.3% and 78.2%,respectively.(2) After 12 weeks treatment,AASI were significantly reduced by 0.13(0.07,0.19),especially in the group of abnormally increased AASI by(0.37 ± 0.16),as compared with the baseline(P 0.01).(3) The incidence of adverse events was 13.4%,including mild dizziness and flushing and palpitation. Conclusion Aranidipine enteric-coated capsules can effectively control 24 h blood pressure and reduce AASI significantly in patients with mild to moderate essential hypertension. And administration of aranidipine is safe.